Cited by 175Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 109 of the 109 references it cites were found in a registry or an index.

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Galluzzi, Lorenzo, Zitvogel, Laurence, Kroemer, Guido·2016·Cancer Immunology Research

Open this paper in CoChat — free account

Abstract

Accumulating preclinical and clinical evidence indicates that the success of several anticancer agents—including some conventional chemotherapeutics, targeted anticancer agents as well as specific forms of radiotherapy—depends (at least in part) on their ability to stimulate anticancer immune responses. Such immunostimulatory effects can be “on-target,” i.e., they originate within cancer cells, or “off-target,” i.e., they develop from a heretofore unsuspected interaction between cancer therapy and the immune system. Here, we briefly discuss the immunologic mechanisms that underlie the efficacy of some forms of cancer therapy, as we highlight the rationale for combining these treatment modalities with immunotherapy to achieve superior therapeutic effects. Cancer Immunol Res; 4(11); 895–902. ©2016 AACR.

Integrity signals

Registry

Crossref · 10.1158/2326-6066.cir-16-0197

Cites

109 of 109 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome
Galon, J., Costes, A., Sanchez-Cabo, F., Kirilovsky, A., Mlecnik, B., Lagorce-Pagès, C., Tosolini, M., Camus, M., Berger, A., Wind, P., et al. (2006) · Science · doi:10.1126/science.1129139 · Cited by 6,516
The future of immune checkpoint therapy
Sharma, P., & Allison, J. P. (2015) · Science · doi:10.1126/science.aaa8172 · Cited by 4,878
Neoantigens in cancer immunotherapy
Schumacher, T. N., & Schreiber, R. D. (2015) · Science · doi:10.1126/science.aaa4971 · Cited by 4,783
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237
Immunogenic cell death and DAMPs in cancer therapy
Krysko, D. V., Garg, A. D., Kaczmarek, A., Krysko, O., Agostinis, P., & Vandenabeele, P. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3380 · Cited by 3,223
Calreticulin exposure dictates the immunogenicity of cancer cell death
Obeid, M., Tesniere, A., Ghiringhelli, F., Fimia, G. M., Apetoh, L., Perfettini, J.-L., Castedo, M., Mignot, G., Panaretakis, T., Casares, N., et al. (2007) · Nature Medicine · doi:10.1038/nm1523 · Cited by 3,216
Self-citation
Immunogenic cell death in cancer and infectious disease
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.107 · Cited by 3,119
Self-citation
Toll-like receptor 4–dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
Apetoh, L., Ghiringhelli, F., Tesniere, A., Obeid, M., Ortiz, C., Criollo, A., Mignot, G., Maiuri, M. C., Ullrich, E., Saulnier, P., et al. (2007) · Nature Medicine · doi:10.1038/nm1622 · Cited by 3,056 · cited 2×
“For instance, loss-offunction alleles of P2RX7 (55), TLR4 (52, 56), FPR1 (51, 56), and Toll-like receptor 3 (TLR3, which is involved in type I IFN signaling; ref.”
BackgroundSelf-citation
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896

Show all 109 references

Sorted by citations

Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018.
Galluzzi, L., Vitale, I., Aaronson, S. A., Abrams, J. M., Adam, D., Agostinis, P., Alnemri, E. S., Altucci, L., Amelio, I., Andrews, D. W., et al. (2018) · Cell Death & Differentiation · doi:10.1038/s41418-017-0012-4 · Cited by 6,680
Self-citation
Mitochondrial control of inflammation
Marchi, S., Guilbaud, E., Tait, S. W. G., Yamazaki, T., & Galluzzi, L. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00760-x · Cited by 1,027
Self-citation
Trial watch: Immunogenic cell death induction by anticancer chemotherapeutics
Garg, A. D., More, S., Rufo, N., Meçe, O., Sassano, M. L., Agostinis, P., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1386829 · Cited by 288
Self-citation
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., Ruysscher, D. D., Tejpar, S., Vandenberghe, P., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 231
Self-citation
Radiation-induced Cell Death and Its Mechanisms
Jiao, Y., Cao, F., & Liu, H. (2022) · Health Physics · doi:10.1097/hp.0000000000001601 · Cited by 239
Killers 2.0: NK cell therapies at the forefront of cancer control
Hodgins, J. J., Khan, S., Park, M. M., Auer, R. C., & Ardolino, M. (2019) · Journal of Clinical Investigation · doi:10.1172/jci129338 · Cited by 213
Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma
Bröckelmann, P. J., Goergen, H., Keller, U. B., Meißner, J., Ordemann, R., Halbsguth, T. V., Sasse, S., Sökler, M., Kerkhoff, A., Mathas, S., et al. (2020) · JAMA Oncology · doi:10.1001/jamaoncol.2020.0750 · Cited by 175
White paper on plasma for medicine and hygiene: Future in plasma health sciences
Bekeschus, S., Favia, P., Robert, É., & von Woedtke, T. (2018) · Plasma Processes and Polymers · doi:10.1002/ppap.201800033 · Cited by 174
Trial watch: Peptide-based vaccines in anticancer therapy
Bezu, L., Kepp, O., Cerrato, G., Pol, J. G., Fucikova, J. P., Špíšek, R., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1511506 · Cited by 158
Self-citation
Research progress on morphology and mechanism of programmed cell death
Chen, Y., Li, X., Yang, M., & Liu, S. (2024) · Cell Death and Disease · doi:10.1038/s41419-024-06712-8 · Cited by 168
Metabolic modulation of immune checkpoints and novel therapeutic strategies in cancer
Wang, Y., Wang, Y., Ren, Y., Zhang, Q., Yi, P., & Cheng, C. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.010 · Cited by 148
Senescence and the tumor-immune landscape: Implications for cancer immunotherapy
Chibaya, L., Snyder, J. T., & Ruscetti, M. A. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2022.02.005 · Cited by 146
Chemotherapeutic and targeted drugs-induced immunogenic cell death in cancer models and antitumor therapy: an update review
Zhai, J., Gu, X., Liu, Y., Hu, Y., Jiang, Y., & Zhang, Z. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1152934 · Cited by 131
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications
Buqué, A., Bloy, N., Aranda, F., Castoldi, F., Eggermont, A. M. M., Cremer, I., Fridman, W. H., Fucikova, J. P., Galon, J., Marabelle, A., et al. (2015) · OncoImmunology · doi:10.1080/2162402x.2015.1008814 · Cited by 132
Self-citation
Role of immune-checkpoint inhibitors in lung cancer
Jain, P., Jain, C., & Velcheti, V. (2018) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465817750075 · Cited by 130
Efficacy of chemotherapy or chemo‐anti‐PD‐1 combination after failed anti‐PD‐1 therapy for relapsed and refractory hodgkin lymphoma: A series from lysa centers
Rossi, C., Gilhodes, J., Maerevoet, M., Herbaux, C., Morschhauser, F., Brice, P., Garciaz, S., Borel, C., Ysebaert, L., Obéric, L., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25154 · Cited by 119
Pembrolizumab plus chemotherapy versus chemotherapy alone in patients with advanced non–small cell lung cancer without tumor PD‐L1 expression: A pooled analysis of 3 randomized controlled trials
Borghaei, H., Langer, C. J., Paz‐Ares, L., Rodríguez‐Abreu, D., Halmos, B., Garassino, M. C., Houghton, B., Kurata, T., Cheng, Y., Lin, J., et al. (2020) · Cancer · doi:10.1002/cncr.33142 · Cited by 115
Naturally-Occurring Invasive Urothelial Carcinoma in Dogs, a Unique Model to Drive Advances in Managing Muscle Invasive Bladder Cancer in Humans
Knapp, D. W., Dhawan, D., Ramos, J. A., Ratliff, T. L., Cresswell, G. M., Utturkar, S. M., Sommer, B. C., Fulkerson, C. M., & Hahn, N. M. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2019.01493 · Cited by 108
Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer
Kašíková, L., Raková, J., Hensler, M., Láníčková, T., Tománková, J., Pasulka, J., Drozenová, J., Mojžíšová, K., Fialová, A., Vosahlikova, S., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-46873-w · Cited by 111
Self-citation
Targeting the Immunomodulatory CD73/Adenosine System to Improve the Therapeutic Gain of Radiotherapy
de Leve, S., Wirsdörfer, F., & Jendrossek, V. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00698 · Cited by 93
Perturbing mitosis for anti‐cancer therapy: is cell death the only answer?
Haschka, M. D., Karbon, G., Fava, L. L., & Villunger, A. (2018) · EMBO Reports · doi:10.15252/embr.201745440 · Cited by 95
Combined treatment of non‐small cell lung cancer using radiotherapy and immunotherapy: challenges and updates
Shang, S., Liu, J., Verma, V., Wu, M., Welsh, J. W., Yu, J., & Chen, D. (2021) · 癌症：英文版 · doi:10.1002/cac2.12226 · Cited by 91
Immune recognition of irradiated cancer cells
Wennerberg, E., Vanpouille‐Box, C., Bornstein, S., Yamazaki, T., Demaria, S., & Galluzzi, L. (2017) · Immunological Reviews · doi:10.1111/imr.12568 · Cited by 88
Self-citation
Dna Damage Response Alterations in Gastric Cancer: Knocking down a New Wall
Ricci, A. D., Rizzo, A., & Brandi, G. (2021) · Future Oncology · doi:10.2217/fon-2020-0989 · Cited by 86
Present and future of cancer immunotherapy: A tumor microenvironmental perspective (Review)
Yu, Y., & Cui, J. (2018) · Oncology Letters · doi:10.3892/ol.2018.9219 · Cited by 80
Immunogenomic Analyses of Advanced Serous Ovarian Cancer Reveal Immune Score is a Strong Prognostic Factor and an Indicator of Chemosensitivity
Hao, D., Liu, J., Chen, M., Li, J., Wang, L., Li, X., Zhao, Q., & Di, L. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-3862 · Cited by 77
Trial Watch: Adoptively transferred cells for anticancer immunotherapy
Fournier, C., Martin, F., Zitvogel, L., Kroemer, G., Galluzzi, L., & Apétoh, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1363139 · Cited by 79
Self-citation
Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy
Michelakos, T. P., Cai, L., Villani, V., Sabbatino, F., Kontos, F., Castillo, C. F.-D., Yamada, T., Neyaz, A., Taylor, M. S., Deshpande, V., et al. (2020) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaa073 · Cited by 75
Nidogen-1 is a novel extracellular ligand for the NKp44 activating receptor
Gaggero, S., Bruschi, M., Petretto, A., Parodi, M., Zotto, G. D., Lavarello, C., Prato, C., Santucci, L., Barbuto, A., Bottino, C., et al. (2018) · Oncoimmunology · doi:10.1080/2162402x.2018.1470730 · Cited by 62
Naturally-occurring canine invasive urothelial carcinoma harbors luminal and basal transcriptional subtypes found in human muscle invasive bladder cancer
Dhawan, D., Hahn, N. M., Ramos, J. A., & Knapp, D. W. (2018) · PLoS Genetics · doi:10.1371/journal.pgen.1007571 · Cited by 73
Cancer Vaccines: Promising Therapeutics or an Unattainable Dream
Donninger, H., Li, C., Eaton, J. W., & Yaddanapudi, K. (2021) · Vaccines · doi:10.3390/vaccines9060668 · Cited by 74
Trial watch: immune checkpoint blockers for cancer therapy
Vanpouille-Box, C., Lhuillier, C., Bezu, L., Aranda, F., Yamazaki, T., Kepp, O., Fucikova, J., Spisek, R., Demaria, S., Formenti, S. C., et al. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1373237 · Cited by 73
Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications
Zhao, B., Wu, B. C., Feng, N., Zhang, X., Zhang, X., Wei, Y., & Zhang, W. (2023) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01426-4 · Cited by 68
Immuno-oncology-101: overview of major concepts and translational perspectives
Allard, B., Aspeslagh, S., Garaud, S., Dupont, F., Solinas, C., Kok, M., Routy, B., Sotiriou, C. P., Stagg, J., & Buisseret, L. (2018) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2018.02.005 · Cited by 60
Natural Compounds of Marine Origin as Inducers of Immunogenic Cell Death (ICD): Potential Role for Cancer Interception and Therapy
Sansone, C., Bruno, A., Piscitelli, C., Baci, D., Fontana, A., Brunet, C., Noonan, D. M., & Albini, A. (2021) · Cells · doi:10.3390/cells10020231 · Cited by 55
Potentiating anti-tumor immunity with physical plasma
Bekeschus, S., Clemen, R., & Metelmann, H. (2018) · Clinical Plasma Medicine · doi:10.1016/j.cpme.2018.10.001 · Cited by 51
Exploiting NK Cell Surveillance Pathways for Cancer Therapy
Barrow, A., & Colonna, M. (2019) · Cancers · doi:10.3390/cancers11010055 · Cited by 48
Radiation-Induced Transformation of Immunoregulatory Networks in the Tumor Stroma
Martínez-Zubiaurre, I., Chalmers, A. J., & Hellevik, T. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.01679 · Cited by 52
Naturally-Occurring Canine Invasive Urothelial Carcinoma: A Model for Emerging Therapies
Sommer, B. C., Dhawan, D., Ratliff, T. L., & Knapp, D. W. (2018) · Bladder Cancer · doi:10.3233/blc-170145 · Cited by 50
Synergizing systemic responses by combining immunotherapy with radiotherapy in metastatic non-small cell lung cancer: The potential of the abscopal effect
Theelen, W. S. M. E., de Jong, M. C., & Baas, P. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.02.015 · Cited by 50
Current Landscape of Immunotherapy for the Treatment of Metastatic Non-Small-Cell Lung Cancer
Pabani, A., & Butts, C. A. (2018) · Current Oncology · doi:10.3747/co.25.3750 · Cited by 48
Ionizing Radiation Curtails Immunosuppressive Effects From Cancer-Associated Fibroblasts on Dendritic Cells
Berzaghi, R., Tornaas, S., Lode, K., Hellevik, T., & Martínez-Zubiaurre, I. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.662594 · Cited by 46
Proteolytic chemokine cleavage as a regulator of lymphocytic infiltration in solid tumors
Bronger, H., Magdolen, V., Goettig, P., & Dreyer, T. F. (2019) · Cancer and Metastasis Reviews · doi:10.1007/s10555-019-09807-3 · Cited by 46
The blood mMDSC to DC ratio is a sensitive and easy to assess independent predictive factor for epithelial ovarian cancer survival
Santegoets, S. J. A. M., de Groot, A. F., Dijkgraaf, E. M., Simões, A. M. C., van der Noord, V. E., van Ham, J. J., Welters, M. J. P., Kroep, J. R., & van der Burg, S. H. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1465166 · Cited by 44
Diagnosis and treatment of epidural metastases.
Grossman, S. A., & Lossignol, D. (1990) · PubMed · Cited by 40
Plasma cell infiltration and treatment effect in breast cancer patients treated with neoadjuvant chemotherapy
Sakaguchi, A., Horimoto, Y., Onagi, H., Ikarashi, D., Nakayama, T., Nakatsura, T., Shimizu, H., Kojima, K., Yao, T., Matsumoto, T., et al. (2021) · Breast Cancer Research · doi:10.1186/s13058-021-01477-w · Cited by 38
Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer
Jie, C., Li, R., Cheng, Y., Wang, Z., Wu, Q., & Xie, C. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1122352 · Cited by 37
Trial Watch: Immunostimulatory monoclonal antibodies for oncological indications
Cabo, M., Offringa, R., Zitvogel, L., Kroemer, G., Muntasell, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1371896 · Cited by 37
Self-citation
Chemoradiation triggers antitumor Th1 and tissue resident memory-polarized immune responses to improve immune checkpoint inhibitors therapy
Joseph, E. L. M., Kirilovsky, A., Lecoester, B., Sissy, C. E., Boullerot, L., Rangan, L., Marguier, A., Tochet, F., Dosset, M., Boustani, J., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002256 · Cited by 42
Trial Watch: combination of tyrosine kinase inhibitors (TKIs) and immunotherapy
Petrazzuolo, A., Maiuri, M. C., Zitvogel, L., Kroemer, G., & Kepp, O. (2022) · OncoImmunology · doi:10.1080/2162402x.2022.2077898 · Cited by 39
Self-citation
Less is more: Exploring neoadjuvant immunotherapy as a de-escalation strategy in head and neck squamous cell carcinoma treatment
Cao, L., Zhong, N., Chen, Y., Li, Z., Wang, G.-R., Xiao, Y., Liu, X.-H., Jia, J., Liu, B., & Bu, L. (2024) · Cancer Letters · doi:10.1016/j.canlet.2024.217095 · Cited by 38
Immunotherapy in Ovarian Cancer
Wang, W., Liu, J. R., & Zou, W. (2019) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2019.02.002 · Cited by 36
Diagnosis and treatment of epidural metastases
Yáñez, M. L., Miller, J. J., & Batchelor, T. T. (2016) · Cancer · doi:10.1002/cncr.30521 · Cited by 36
Safety and efficacy of p62 DNA vaccine ELENAGEN in a first-in-human trial in patients with advanced solid tumors
Ponomarenko, D. M., Клімова, І., Chapygina, Y. A., Dvornichenko, V. V., Zhukova, N. V., Орлова, Р. В., Manikhas, G. M., Zyryanov, A. V., Бурханова, Л. А., Badrtdinova, I. I., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.16574 · Cited by 36
Systemic autophagy in the therapeutic response to anthracycline-based chemotherapy
Castoldi, F., Vacchelli, E., Zitvogel, L., Maiuri, M. C., Pietrocola, F., & Kroemer, G. (2019) · OncoImmunology · doi:10.1080/2162402x.2018.1498285 · Cited by 33
Self-citation
Phase I/II Trial of Vemurafenib in Dogs with Naturally Occurring, BRAF -mutated Urothelial Carcinoma
Rossman, P., Zabka, T. S., Ruple, A., Tuerck, D., Ramos, J. A., Liu, L., Mohallem, R., Merchant, M. A., Franco, J., Fulkerson, C. M., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0893 · Cited by 33
Immune-based combination therapy for esophageal cancer
Wang, H., Xu, Y., Zuo, F., Liu, J., & Yang, J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1020290 · Cited by 33
Targeted Therapies: Immunologic Effects and Potential Applications Outside of Cancer
Kersh, A. E., Ng, S., Chang, Y. M., Sasaki, M., Thomas, S. N., Kissick, H. T., Lesinski, G. B., Kudchadkar, R. R., Waller, E. K., & Pollack, B. P. (2017) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.1028 · Cited by 33
Trial watch: DNA-based vaccines for oncological indications
Pierini, S., Perales-Linares, R. F., Uribe‐Herranz, M., Pol, J. G., Zitvogel, L., Kroemer, G., Facciabene, A., & Galluzzi, L. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1398878 · Cited by 29
Self-citation
Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?
Filippi, A. R., Muzio, J. D., Badellino, S., Mantovani, C., & Ricardi, U. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2017.12.53 · Cited by 29
Neoadjuvant with low-dose radiotherapy, tislelizumab, albumin-bound paclitaxel, and cisplatin for resectable locally advanced head and neck squamous cell carcinoma: phase II single-arm trial
Liu, Z., Wang, D., Yi, M., Yi, M., Zhang, Z., Zhong, G., Xu, L., Jiang, R., Zheng, Y., Huang, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-59865-1 · Cited by 31
Can the co-dependence of the immune system and angiogenesis facilitate pharmacological targeting of tumours?
Mortara, L., Benest, A. V., Bates, D. O., & Noonan, D. M. (2017) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2017.05.009 · Cited by 27
Angiogenesis Inhibitors and Immunomodulation in Renal Cell Cancers: The Past, Present, and Future
Kasherman, L., Siu, D. H. W., Woodford, R. G., & Harris, C. A. (2022) · Cancers · doi:10.3390/cancers14061406 · Cited by 29
Prognostic Value of the Lung Immune Prognostic Index May Differ in Patients Treated With Immune Checkpoint Inhibitor Monotherapy or Combined With Chemotherapy for Non-small Cell Lung Cancer
Wang, W., Huang, Z., Yu, Z., Zhuang, W., Zheng, W., Cai, Z., Shi, L., Yu, X., Lou, G., Hong, W., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.572853 · Cited by 26
Biomimetic Active Materials Guided Immunogenic Cell Death for Enhanced Cancer Immunotherapy
Huang, G., Liu, L., Pan, H., & Cai, L. (2022) · Small Methods · doi:10.1002/smtd.202201412 · Cited by 25
Type of chemotherapy has substantial effects on the immune system in ovarian cancer
Vankerckhoven, A., Baert, T., Riva, M., Bruyn, C. D., Thirion, G., Vandenbrande, K., Ceusters, J., Vergote, I. B., & Coosemans, A. (2021) · Translational Oncology · doi:10.1016/j.tranon.2021.101076 · Cited by 23
Interactions between Cisplatin and Quercetin at Physiological and Hyperthermic Conditions on Cancer Cells In Vitro and In Vivo
Oršolić, N., Odeh, D., Jembrek, M. J., Knežević, J., & Kučan, D. (2020) · Molecules · doi:10.3390/molecules25143271 · Cited by 25
Immunotherapy-related gastritis: Two case reports and literature review
Woodford, R. G., Briscoe, K. P., Tustin, R., & Jain, A. (2021) · Clinical Medicine Insights Oncology · doi:10.1177/11795549211028570 · Cited by 22
Association of survival and genomic mutation signature with immunotherapy in patients with hepatocellular carcinoma
Ou, Q., Yu, Y., Li, A., Chen, J., Yu, T., Xu, X., Xie, X., Chen, Y., Lin, D., Zeng, Q., et al. (2020) · Annals of Translational Medicine · doi:10.21037/atm.2020.01.32 · Cited by 21
Immune profiling and immunotherapeutic targets in pancreatic cancer
Lenzo, F. L., Kato, S., Pabla, S., DePietro, P., Nesline, M., Conroy, J. M., Burgher, B., Glenn, S. T., Kuvshinoff, B. W., Kurzrock, R., et al. (2021) · Annals of Translational Medicine · doi:10.21037/atm-20-1076 · Cited by 21
Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells
Otsuka, K., Mitsuhashi, A., Goto, H., Hanibuchi, M., Koyama, K., Ogawa, H., Ogino, H., Saijo, A., Kozai, H., Yoneda, H., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.05.023 · Cited by 19
Efficacy and safety of chemotherapy regimens for first-line treatment of advanced esophageal squamous cell carcinoma in Asia: a systematic review
Xu, J., Bai, Y., Li, E., Xu, N., Shi, D., & Qian, J. (2022) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2022.2110470 · Cited by 17
Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients
Huber, V., Guardo, L. D., Lalli, L., Giardiello, D., Cova, A., Squarcina, P., Frati, P., Giacomo, A. M. D., Pilla, L., Tazzari, M., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-001167 · Cited by 17
Pembrolizumab Plus Chemotherapy Versus Chemotherapy Monotherapy as a First-Line Treatment in Elderly Patients (≥75 Years Old) With Non-Small-Cell Lung Cancer
Yang, Z., Chen, Y., Wang, Y., Hu, M., Qian, F., Zhang, Y., Zhang, B., Zhang, W., & Han, B. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.807575 · Cited by 17
Immunotherapeutic Strategies in Non-Small-Cell Lung Cancer: The Present and the Future
Steendam, C. M. J., Dammeijer, F. F., Aerts, J. G. J. V., & Cornelissen, R. (2017) · Immunotherapy · doi:10.2217/imt-2016-0151 · Cited by 15
Phase I/II clinical trial of the targeted chemotherapeutic drug, folate-tubulysin, in dogs with naturally-occurring invasive urothelial carcinoma
Szigetvari, N. M., Dhawan, D., Ramos, J. A., Leamon, C. P., Klein, P. J., Ruple, A., Heng, H. G., Pugh, M. R., Rao, S. B., Vlahov, I. R., et al. (2018) · Oncotarget · doi:10.18632/oncotarget.26455 · Cited by 16
Can Tumor-Infiltrating Lymphocytes (TILs) Be a Predictive Factor for Lymph Nodes Status in Both Early Stage and Locally Advanced Breast Cancer?
Caziuc, A., Schlanger, D., Amarinei, G., & Dindelegan, G. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8040545 · Cited by 16
Efficacy and Safety of HAIC-FOLFOX Plus Tyrosine Kinase Inhibitors and Immune Checkpoint Inhibitors as First-line Treatment for Unresectable Advanced Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis
Jiang, P., Chen, C., Tian, J., Yang, F., Jiang, Z., Hu, A., & Liu, B. (2024) · Academic Radiology · doi:10.1016/j.acra.2024.09.061 · Cited by 15
Multiplexed In Situ Spatial Protein Profiling in the Pursuit of Precision Immuno-Oncology for Patients with Breast Cancer
Massa, D., Tosi, A., Rosato, A., Guarneri, V., & Dieci, M. V. (2022) · Cancers · doi:10.3390/cancers14194885 · Cited by 17
Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory
Bloom, A. C., Bender, L. H., Tiwary, S., Pasquet, L., Clark, K. T., Jiang, T., Zheng, X., Morales‐Kastresana, A., Jones, J. C., Walters, I. B., et al. (2019) · OncoImmunology · doi:10.1080/2162402x.2019.1625687 · Cited by 16
Combining Radiation Therapy With Interferons: Back to the Future
Goedegebuure, R. S. A., Vonk, C. M., Kooij, L. P., Derks, S., & Thijssen, V. L. (2020) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2020.02.016 · Cited by 16
Cell Identity and Spatial Distribution of PD‐1/PD‐L1 Blockade Responders
Li, X., Liu, Y., Gui, J., Gan, L., & Xue, J. (2024) · Advanced Science · doi:10.1002/advs.202400702 · Cited by 17
Combined treatment of small cell lung cancer using radiotherapy and immunotherapy: Challenges and updates
Cao, Z., Deng, K., Jiang, J., Tian, K., & Wang, B. (2024) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2024.117727 · Cited by 16
Conditioning neoadjuvant therapies for improved immunotherapy of cancer
Benson, Z., Manjili, S. H., Habibi, M., Guruli, G., Toor, A. A., Payne, K. K., & Manjili, M. H. (2017) · Biochemical Pharmacology · doi:10.1016/j.bcp.2017.08.007 · Cited by 14
Review to Understand the Crosstalk between Immunotherapy and Tumor Metabolism
Pandey, P., Khan, F., Upadhyay, T. K., & Maqsood, R. (2023) · Molecules · doi:10.3390/molecules28020862 · Cited by 13
Basal and Luminal Molecular Subtypes in Naturally-Occurring Canine Urothelial Carcinoma are Associated with Tumor Immune Signatures and Dog Breed
Sommer, B. C., Dhawan, D., Ruple, A., Ramos, J. A., Hahn, N. M., Utturkar, S. M., Ostrander, E. A., Parker, H. G., Fulkerson, C. M., Childress, M. O., et al. (2021) · Bladder Cancer · doi:10.3233/blc-201523 · Cited by 12
A Prognostic Model Based on Residual Cancer Burden and Tumor-Infiltrating Lymphocytes on Residual Disease after Neoadjuvant Therapy in HER2+ Breast Cancer
Miglietta, F., Ragazzi, M., Fernandes, B., Griguolo, G., Massa, D., Girardi, F., Bottosso, M., Bisagni, A., Zarrilli, G., Porra, F., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-0480 · Cited by 12
Searching for Goldilocks: How Evolution and Ecology Can Help Uncover More Effective Patient-Specific Chemotherapies
Park, D. S., Luddy, K. A., Robertson‐Tessi, M., O’Farrelly, C., Gatenby, R. A., & Anderson, A. R. A. (2020) · Cancer Research · doi:10.1158/0008-5472.can-19-3981 · Cited by 12
Induction treatment in patients with stage III non-small cell lung cancer
Palmero, R., Vilariño, N., Navarro-Martín, A., & Nadal, E. (2021) · Translational Lung Cancer Research · doi:10.21037/tlcr-20-420 · Cited by 13
Radiotherapy and PD-L1 inhibition in metastatic NSCLC
Ruysscher, D. D. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30354-6 · Cited by 12
Biology and therapeutic applications of the proton-coupled folate transporter
Matherly, L. H., Schneider, M. J., Gangjee, A., & Hou, Z. (2022) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2022.2136071 · Cited by 11
Role of immunotherapy in pulmonary sarcomatoid carcinoma: review of current approaches and related biomarkers
Ding, K., Peng, Z., & Xu, Y. (2024) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359241249041 · Cited by 12
GRP78 expression in peripheral blood mononuclear cells is a new predictive marker for the benefit of taxanes in breast cancer neoadjuvant treatment
Raiter, A., Lipovettzky, J., Lubin, I., & Yerushalmi, R. (2020) · BMC Cancer · doi:10.1186/s12885-020-06835-z · Cited by 11
Basics of immunotherapy for epithelial ovarian cancer
Collin-Bund, V., Azaïs, H., Bibi‐Triki, S., Lecointre, L., Bétrian, S., Ángeles, M. A., Eberst, L., Faller, É., Boisramé, T., Bendifallah, S., et al. (2021) · Journal of Gynecology Obstetrics and Human Reproduction · doi:10.1016/j.jogoh.2021.102283 · Cited by 11
Systems Immunology Analysis Reveals an Immunomodulatory Effect of Snail-p53 Binding on Neutrophil- and T Cell-Mediated Immunity in KRAS Mutant Non-Small Cell Lung Cancer
Hammoudeh, S. M., Venkatachalam, T., Ansari, A. W., Bendardaf, R., Hamid, Q. A., Rahmani, M., & Hamoudi, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.569671 · Cited by 10
Resistance to Immune Checkpoint Blockade in Uterine Leiomyosarcoma: What Can We Learn from Other Cancer Types?
Wispelaere, W. D., Annibali, D., Tuyaerts, S., Lambrechts, D., & Amant, F. C. (2021) · Cancers · doi:10.3390/cancers13092040 · Cited by 10
Incorporating weekly carboplatin in anthracycline and paclitaxel-containing neoadjuvant chemotherapy for triple-negative breast cancer: propensity-score matching analysis and TIL evaluation
Dieci, M. V., Carbognin, L., Miglietta, F., Canino, F., Giorgi, C. A., Cumerlato, E., Amato, O., Massa, D., Griguolo, G., Genovesi, E., et al. (2022) · British Journal of Cancer · doi:10.1038/s41416-022-02050-8 · Cited by 9
The Determination of Immunomodulation and Its Impact on Survival of Rectal Cancer Patients Depends on the Area Comprising a Tissue Microarray
Gruber, E. S., Oberhuber, G., Pils, D., Störk, T., Sinn, K., Gruber, S., Nica, R., Kolmer, D., Turner, S. D., Schlederer, M., et al. (2020) · Cancers · doi:10.3390/cancers12030563 · Cited by 9
Cisplatin-based chemoradiation decreases telomerase-specific CD4 TH1 response but increases immune suppressive cells in peripheral blood
Boustani, J., Joseph, E. L. M., Martin, E., Benhmida, S., Lecoester, B., Tochet, F., Mirjolet, C., Chevalier, C., Thibouw, D., Vulquin, N., et al. (2021) · BMC Immunology · doi:10.1186/s12865-021-00429-5 · Cited by 12
Modulation of Immuno-biome during Radio-sensitization of Tumors by Glycolytic Inhibitors
Gupta, S., & Dwarakanath, B. S. R. (2018) · Current Medicinal Chemistry · doi:10.2174/0929867325666180601101145 · Cited by 8

Authors: Galluzzi, L., Zitvogel, L., & Kroemer, G.
Affiliations: Inserm (FR)
Université Paris-Sud (FR)
Karolinska University Hospital (SE)
ORCID: Galluzzi, Lorenzo
Zitvogel, Laurence
Kroemer, Guido
Venue: Cancer Immunology Research
Publisher: American Association for Cancer Research (AACR)
Published: 2016-10-31
Volume: 4
Issue: 11
Pages: 895-902
ISSN: 2326-6066 (ISSN-L)
2326-6074
DOI: 10.1158/2326-6066.cir-16-0197
OpenAlex: W2547825706
Cited by: 175
References: 109
Citations by year: 2026: 6 · 2025: 14 · 2024: 13 · 2023: 16 · 2022: 22 · 2021: 24 · 2020: 25 · 2019: 10 · 2018: 29 · 2017: 13 · 2016: 1
FWCI: 1.78
Type: journal article
Language: en
Open access: closed
Locations: Cancer Immunology Research (publishedVersion)
PubMed (publishedVersion)
Funders: Association pour la Recherche sur le Cancer
Ligue Contre le Cancer
Institut National Du Cancer
Institute of Cancer Research
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: cancer immunotherapy, antitumor immunity, chemotherapeutics, targeted anticancer agents, radiotherapy, combination therapy, tumor immunology
MeSH terms: Animals, Antigens, Neoplasm, Combined Modality Therapy, Disease Susceptibility, Humans, Immune System, Neoplasms, Treatment Outcome, Immunomodulation

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Immunological Mechanisms Underneath the Efficacy of Cancer Therapy

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks